Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Improving response to FLT3 inhibitors--BCL2 the rescue?

Perl AE.

Clin Cancer Res. 2019 Sep 12. pii: clincanres.2339.2019. doi: 10.1158/1078-0432.CCR-19-2339. [Epub ahead of print]

PMID:
31515455
2.

Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Perl AE.

Expert Rev Clin Pharmacol. 2019 Sep;12(9):841-849. doi: 10.1080/17512433.2019.1657009. Epub 2019 Aug 27.

PMID:
31454267
3.

Availability of FLT3 inhibitors: how do we use them?

Perl AE.

Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26. Review.

PMID:
31243041
4.

Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.

Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD.

Br J Haematol. 2019 Sep;186(6):801. doi: 10.1111/bjh.16048. Epub 2019 Jun 17. No abstract available.

PMID:
31206598
5.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.

Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31175001
6.

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD, Carroll M, Perl AE.

Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496. No abstract available.

7.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE.

Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.

PMID:
31088841
8.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

9.

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.

Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M.

Blood Adv. 2019 Apr 9;3(7):1061-1072. doi: 10.1182/bloodadvances.2018029850.

10.

Advances in patient care through increasingly individualized therapy.

DiNardo CD, Perl AE.

Nat Rev Clin Oncol. 2019 Feb;16(2):73-74. doi: 10.1038/s41571-018-0156-2. No abstract available.

PMID:
30602758
11.

Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

McMahon CM, Perl AE.

Leuk Lymphoma. 2019 Mar;60(3):583-597. doi: 10.1080/10428194.2018.1504937. Epub 2018 Sep 20.

PMID:
30234399
12.

Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.

Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M, Carroll M, Faryabi RB.

Clin Cancer Res. 2019 Jan 15;25(2):573-583. doi: 10.1158/1078-0432.CCR-18-0655. Epub 2018 Sep 4.

PMID:
30181385
13.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

14.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
15.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE.

Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.

16.

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE.

Invest New Drugs. 2018 Aug;36(4):657-666. doi: 10.1007/s10637-018-0585-x. Epub 2018 Apr 2.

17.

The role of targeted therapy in the management of patients with AML.

Perl AE.

Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829. eCollection 2017 Nov 14. Review.

18.

The most novel of the novel agents for acute myeloid leukemia.

Perl AE.

Curr Opin Hematol. 2018 Mar;25(2):81-89. doi: 10.1097/MOH.0000000000000411. Review.

PMID:
29278535
19.

The role of targeted therapy in the management of patients with AML.

Perl AE.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):54-65. doi: 10.1182/asheducation-2017.1.54. Review.

20.

Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.

Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Ashchyan HJ, Perl AE, James WD, Micheletti RG, Rosenbach M.

J Am Acad Dermatol. 2018 Feb;78(2):303-309.e4. doi: 10.1016/j.jaad.2017.09.013. Epub 2017 Oct 26.

PMID:
29107342
21.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

22.

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP.

Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10.

23.

High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.

Tasian SK, Hurtz C, Wertheim GB, Bailey NG, Lim MS, Harvey RC, Chen IM, Willman CL, Astles R, Zebrowski A, Reshmi SC, Li MM, Frey NV, Luger SM, Carroll M, Perl AE.

Leukemia. 2017 Apr;31(4):981-984. doi: 10.1038/leu.2016.375. Epub 2016 Dec 9. No abstract available.

24.

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA.

Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24.

25.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

26.

Allogeneic transplant for FLT3-ITD+ AML: room for improvement.

Perl AE, Luger SM.

Bone Marrow Transplant. 2016 Apr;51(4):508-10. doi: 10.1038/bmt.2016.37. Epub 2016 Mar 14. No abstract available.

PMID:
26974268
27.

FLT3 Inhibitor-Associated Neutrophilic Dermatoses.

Varadarajan N, Boni A, Elder DE, Bagg A, Micheletti R, Perl AE, Rosenbach M.

JAMA Dermatol. 2016 Apr;152(4):480-2. doi: 10.1001/jamadermatol.2015.6121. No abstract available.

PMID:
26886840
28.

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.

Nybakken GE, Canaani J, Roy D, Morrissette JD, Watt CD, Shah NP, Smith CC, Bagg A, Carroll M, Perl AE.

Leukemia. 2016 Jun;30(6):1422-5. doi: 10.1038/leu.2015.320. Epub 2015 Nov 20. No abstract available.

29.

NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features.

Luskin MR, Huen AO, Brooks SA, Stewart C, Watt CD, Morrissette JJ, Lieberman DB, Bagg A, Rosenbach M, Perl AE.

Haematologica. 2015 Oct;100(10):e412-4. doi: 10.3324/haematol.2015.129346. Epub 2015 Jun 25. No abstract available.

30.

Dynamic evolution of clonal epialleles revealed by methclone.

Li S, Garrett-Bakelman F, Perl AE, Luger SM, Zhang C, To BL, Lewis ID, Brown AL, D'Andrea RJ, Ross ME, Levine R, Carroll M, Melnick A, Mason CE.

Genome Biol. 2014 Sep 27;15(9):472. doi: 10.1186/s13059-014-0472-5.

31.

Crenolanib is a selective type I pan-FLT3 inhibitor.

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi: 10.1073/pnas.1320661111. Epub 2014 Mar 12.

32.

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib.

Schaab C, Oppermann FS, Klammer M, Pfeifer H, Tebbe A, Oellerich T, Krauter J, Levis M, Perl AE, Daub H, Steffen B, Godl K, Serve H.

Leukemia. 2014 Mar;28(3):716-9. doi: 10.1038/leu.2013.347. Epub 2013 Nov 19. No abstract available.

33.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M.

Blood. 2013 Jun 13;121(24):4917-24. doi: 10.1182/blood-2013-03-493197. Epub 2013 May 2.

34.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S.

Am J Hematol. 2013 Aug;88(8):657-60. doi: 10.1002/ajh.23468. Epub 2013 Jun 5.

35.

ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.

Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, Koumenis C.

J Clin Invest. 2012 Dec;122(12):4621-34. doi: 10.1172/JCI62973. Epub 2012 Nov 12.

36.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP.

Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.

37.

Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.

Perl AE, Kasner MT, Shank D, Luger SM, Carroll M.

Clin Cancer Res. 2012 Mar 15;18(6):1716-25. doi: 10.1158/1078-0432.CCR-11-2346. Epub 2011 Dec 13.

38.

Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.

Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB.

Oncogene. 2010 May 20;29(20):2962-72. doi: 10.1038/onc.2010.67. Epub 2010 Mar 15.

39.

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB.

Cancer Cell. 2010 Mar 16;17(3):225-34. doi: 10.1016/j.ccr.2010.01.020. Epub 2010 Feb 18.

40.

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM.

Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.

41.

A robust xenotransplantation model for acute myeloid leukemia.

Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G, Carroll M.

Leukemia. 2009 Nov;23(11):2109-17. doi: 10.1038/leu.2009.143. Epub 2009 Jul 23.

42.

A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.

Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M.

Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185.

43.

Exploiting signal transduction pathways in acute myelogenous leukemia.

Perl AE, Carroll M.

Curr Treat Options Oncol. 2007 Aug;8(4):265-76. Review.

PMID:
18097642

Supplemental Content

Support Center